SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. has announced a new approach to hair transplantation developed using frozen cryopreserved hair follicles. Healthy mouse hair follicles were cryopreserved at -80oC. Upon thawing and transplantation to hairless “nude” mice, the transplanted follicles produced extensive hair growth similar to fresh follicles. The new study is published in PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0145997).
“The ability to transplant cryopreserved hair follicles can allow cancer patients and others to bank their hair follicles for future use if they wish”, said Charlene Cooper, Vice President and Chief Operating Officer of AntiCancer Inc. “The cryopreserved follicles also contain hair-follicle-associated-pluripotent (HAP) stem cells, which have shown in previous studies potential in mouse models for repair of nerves and spinal cords and possibly heart muscle,” said Ms. Cooper.
AntiCancer Inc., founded in 1984 and based in San Diego, with offices and laboratories in Seoul, Beijing, Nanjing and Tokyo, has developed the leading mouse models of cancer including MetaMouse®, AngioMouse® and StromaMouse®. These mouse models are made imageable with AntiCancer’s OncoBrite® technology and are the models of choice for novel drug discovery for cancer. With its proprietary mouse models, AntiCancer is the foremost pre-clinical cancer contract research organization. The proprietary mouse models are also available via licensing. AntiCancer offers the world’s largest collection of fluorescent-protein-expressing cancer cell lines and transgenic fluorescent nude mice. AntiCancer is a pioneer in fluorescence-guided surgery of cancer using its patient-like mouse models. AntiCancer is also developing biological drugs that target cancer-specific metabolic defects, including recombinant methioninase (rMETase). AntiCancer developed the Histoculture Drug Response Assay (HDRA) and patient-derived orthotopic xenografts (PDOXTM) for individualized cancer treatment. AntiCancer is also developing tumor-targeting bacteria for the general cure of cancer. The company markets recombinant-enzyme-based diagnostics for cancer and cardiovascular disease in its wholly-owned A/C Diagnostics LLC subsidiary.